This post was just published on ZYX Buy Change Alert. A large number of subscribers are holding General Cable (BGC) stock from $10. Newer subscribers are holding BGC from as high as $21. BGC has received a $30 cash buyout offer from Prysmian Group. The Arora Report had previously identified BGC as a takeover
Not long ago, French pharmaceutical company Advanced Accelerator Applications got a lot of publicity. Now it’s getting bought out. The late Apple AAPL, co-founder Steve Jobs died from pancreatic cancer, specifically from a neuroendocrine tumor, or islet cell carcinoma. Advanced Accelerator Applications AAAP, became famous because of its work on
This post was just published on ZYX Buy Change Alert. Advanced Accelerator Applications (AAAP) stock is long from $40.50. AAAP has received an $82 cash buyout offer from Novartis (NVS). You have doubled your money if you followed us on this trade. This is 130th buyout or M&A of one of our portfolio
This post was just published on ZYX Buy Change Alert. Advanced Accelerator Applications (AAAP) stock is long from $40.50. As of this writing it is trading at $66.65. AAAP’s lutetium, the treatment for the cancer that killed Steve Jobs of Apple (AAPL), has been approved by the European Commission. This good news is
This post was published on ZYX Buy Change Alert. Advanced Accelerator Application (AAAP) stock is long from $40.50. It traded as high as $70 in the pre market before pulling back on rumors that Novartis (NVS) will make a buyout offer. If a buyout occurs it will be 129th buyout of one of our
This post was just published on ZYX Buy Change Alert. AAAP, Steve Jobs cancer drug company, appears to be breaking out. Please see prior post on AAAP. This information is useful only for short-term aggressive traders. Long-term conservative investors may ignore this post. You are receiving less than 2% of the content
I’m constantly exposed to speculative biotechnology companies with promising treatments. But few pass our investing screens. Advanced Accelerator Applications SA AAAP, a 15-year-old French radiopharmaceutical company, has been getting a lot of publicity. The company claims to be close to bringing to market a therapy that targets the cancer that